Table 2 Bias assessment of the included cohort studies
From: SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review
Included studies | Selections | Comparability | Outcome | Total score | |||||
|---|---|---|---|---|---|---|---|---|---|
Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of Interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow up long enough for outcomes to occur | Adequacy of follow up of cohorts | ||
Barak Mizrahi-2021.11 [12] | * | * | * | * | ** | * | 0 | * | 8 |
LaithJ.Abu-Raddad,-2021.11 [13] | * | * | * | 0 | ** | * | * | 0 | 7 |
Aharona Glatman-Freedman-2021.10 [14] | * | * | * | * | ** | * | 0 | 0 | 7 |
Yinon M. Bar-ON-2022.4 [17] | * | * | * | * | ** | * | 0 | * | 8 |
Sara Y Tartof -2021.10 [6] | * | * | * | 0 | ** | * | * | 0 | 7 |
Utkarsh Agrawal-2021.12 [18] | * | * | * | 0 | ** | * | 0 | 0 | 6 |
Eli S. Rosenberg,-2021.12 [19] | * | * | * | * | ** | * | 0 | 0 | 7 |
Ori Magen-2022.4 [20] | * | * | 0 | * | ** | * | 0 | 0 | 6 |
J. Daniel Kelly,-2022.9 [23] | 0 | * | * | 0 | ** | * | * | 0 | 6 |
Eric J Haas-2021.5 [25] | * | * | * | * | ** | * | 0 | 0 | 7 |
Giulia Vivaldi-2022.9 [32] | * | * | 0 | 0 | ** | 0 | * | 0 | 5 |
Alejandro Jara-2021.7 [33] | * | * | * | * | ** | * | 0 | 0 | 7 |
Sharon Hui Xuan Tan 2022.2 [34] | * | * | * | * | ** | * | 0 | 0 | 7 |
Jennifer M. Polinski 2022.3 [35] | * | * | * | * | ** | * | * | * | 9 |
Tyler N. A. Winkelman 2022.3 [36] | * | * | * | * | ** | * | * | * | 9 |
Massimo Fabiani 2022.2 [37] | * | * | * | * | ** | * | * | 0 | 8 |
Julia Hippisley-Cox 2021.9 [38] | * | * | * | * | ** | * | * | 0 | 8 |
Peter Nordstrom 2022.3 [39] | * | * | * | 0 | ** | * | * | 0 | 7 |
Srinivasa Vittal Katikireddi 2022.1 [40] | * | * | * | * | ** | * | * | * | 9 |